FKBP12 oligonucleotide antisense therapy (Ionis Pharmaceuticals)

N/A

Report date: 2025/03/20 14:47:55
NME

Base Information

Drug NameFKBP12 oligonucleotide antisense therapy (Ionis Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionFK506-binding protein 1A degraders
TargetsFK506-binding protein 1A
Therapy Area/IndicationsIron Overload
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesIonis Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsIron Overload
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A